i s t r y , O 0 Rheumatology -I t a l y U t i l i z i n g the very s a t i s f a c t o r y HPLC procedure recently r e p o r t ed by Hughes e t a l . ( I ) , we have determined the u r i n a r y excret i o n o f o x a l i c acid i n control subjects (aged 20 t o 70 years) and i n gouty patients (from 35 t o 73 years), before and a f t e r allopur i n o l treatment. The u r i n a r y excretion i n normal subjects was 27.5* 1.89 mg/24h, i n gouty patients 31.3f 3.08 mgl24h before a llopurinol , and 43.22 k4.66 mg/24h a f t e r treatment. I t i s evident t h a t there i s no substantial difference between normal subjects and gouty patients, while a l l o p u r i n o l s i g n i f i c a n t l y increases (p 40.05) the u r i n a r y excretion o f o x a l i c acid. Since a l l o p u r i n o l i n h i b i t s the incorporation o f glycine i n t o purine ribonucleotides, t h i s increase suggests t h a t the glycine might be channeled toward the formation o f glyoxylate and o x a l i c acid i n gouty pat i e n t s (2).Results suggest t h a t the behavior o f u r i n a r y oxalic a s i d should be under constant control during a l l o p u r i n o l treatment. In contrast, NECA, 2-CIA, A and (-1-R-PIA, in U M concentrations, enhanced the release of both histamine and LTC4 from mast cells purified from human lung. The effect of A and its analogs was not blocked by dipyridamole and partially inhibited by T.
These results support the hypothesis that adenosine and its analogs produce distinct biological effect in the modulation of mediator release from human basophils and lung mast cells. Stimulated mast c e l l s produce and release adenosine, and the release o f mast c e l l mediators i s potentiated by adenosine, y e t very l i t t l e i s known regarding mast c e l l purine metabolism. Because AICAR has been shown t o a l t e r metabolism o f adenosine and accelerate the r e p l e t i o n of ATP pools i n other tissues, i t s e f f e c t on mast c e l l function was examined. Simultaneous addition of AICAR (25- With t h i s technique we have compared ADA enzyme a c t i v i t y and mRNA levels i n lymphoblastoid c e l l l i n e s and lymphocytes from leukemic patients. Our data i n d i c a t e t h a t ,there may be both t r a n s c r i p t i o n a l and post-transcriptional control mechanisms f o r ADA. The use o f b i o t i n y l a t e d DNA sequences as hybridization probes provides a sensitive, stable, and rapid method f o r quantitating s p e c i f i c mRNA levels, and should be applicable t o other systems. A nucleotide analysis of Bloom's syndrome lymphocytes and f i b r o b l a s t s has revealed a p a r t i a l depletion i n adenine nucleotide pools. ATPIADP r a t i o i n these c e l l s was a t l e a s t three-fold lower than i n primary cultures o f normal human c e l l s . Fractionation o f each adenine nucleotide by high performance l i q u i d chromatography showed t h a t differences d i d not r e f l e c t an excess i n ADP but rather low l e v e l s o f ATP i n Bloom's syndrome cultures. Moreover, such low energy state has been correlated w i t h t h e i r low growth. Recent data from our laboratory indicate t h a t Bloom's syndrome c e l l s may r e f l e c t an impaired salvage pathway o f purine biosynthesis since these c e l l s appear t o be defective o r even lack adenine phosphoribosyl transferase (APRT) a c t i v i t y . Our work mainly focuses on the k i n e t i c s o f purine salvage pathway i n Bloom's syndrome c e l l s , as well as on drug resistance (cytotoxic purine analogs), i n order t o characterize the extent o f the defect.
LOW ADENINE NUCLEOTIDE POOLS IN BLOOM' S SYNDROME

